RET and thyroid nodule: This early version is characterized by a panel including four DNA point mutations (BRAF, HRAS, NRAS, and KRAS) and three RNA translocation fusion markers (RET/PTC1, RET/PTC3, and PAX8/PPARγ) with high specificity to rule-in malignancy in indeterminate thyroid nodules (23).